Drug Market Dynamics
Novo Nordisk faces significant challenges with a 30% drop in stock over the past year, primarily due to failed trials for a new drug. However, recent earnings show a promising turnaround with Wegovy sales more than doubling and overall GLP1 business growth exceeding 50%. This shift highlights the critical importance of the obesity drug market for the company's future.In this clip
From this podcast
The Prof G Pod with Scott Galloway
Prof G Markets: Spotify’s First Year of Profitability + Is Google Losing its Edge?
Related Questions